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Abstract
Background: Diseased tendons are characterised by fibrotic scar tissue, which adversely affects tendon structure
and function and increases the likelihood of re-injury. The mechanisms and expression profiles of fibrosis in
diseased tendon is understudied compared to pulmonary and renal tissues, where transforming growth factor
(TGF)β and its associated superfamily are known to be key drivers of fibrosis and modulate extracellular matrix
homeostasis. We hypothesised that differential expression of TGFβ superfamily members would exist between
samples of human rotator cuff tendons with established disease compared to healthy control tendons.
Methods: Healthy and diseased rotator cuff tendons were collected from patients presenting to an orthopaedic
referral centre. Diseased tendinopathic (intact) and healthy rotator cuff tendons were collected via ultrasound-guided
biopsy and torn tendons were collected during routine surgical debridement. Immunohistochemistry and quantitative
real-time polymerase chain reaction were used to investigate the protein and gene expression profiles of TGFβ
superfamily members in these healthy and diseased tendons.
Results: TGFβ superfamily members were dysregulated in diseased compared to healthy tendons. Specifically, TGFβ-1,
TGFβ receptor (R)1 and TGFβ R2 proteins were reduced (p < 0.01) in diseased compared to healthy tendons. At the
mRNA level, TGFβ R1 was significantly reduced in samples of diseased tendons, whereas TGFβ R2 was increased
(p < 0.01). BMP-2, BMP-7 and CTGF mRNA remained unchanged with tendon disease.
Conclusions: We propose that downregulation of TGFβ pathways in established tendon disease may be a
protective response to limit disease-associated fibrosis. The disruption of the TGFβ axis with disease suggests
associated downstream pathways may be important for maintaining healthy tendon homeostasis. The findings
from our study suggest that patients with established tendon disease would be unlikely to benefit from
therapeutic TGFβ blockade, which has been investigated as a treatment strategy in several animal models. Future
studies should investigate the expression profile of fibrotic mediators in earlier stages of tendon disease to
improve understanding of the targetable mechanisms underpinning tendon fibrosis.
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Background
Musculoskeletal diseases are a common cause of pain
and disability in well-resourced health systems [1].
Shoulder pain is the third most common cause of mus-
culoskeletal pain, accounting for 2.4 % of all general
practitioner consultations annually in the UK [2]. Shoul-
der pain is frequently treated conservatively, but after
1 year 41 % of patients have persistent pain [3]. Rotator
cuff disease is the major cause of shoulder pain with the
supraspinatus tendon being most frequently affected [4].
The onset of tendon pathology is associated with ageing,
chronic overuse and genetic predisposition [5–7]. Shoul-
der pain is a major socio-economic burden and joint
failure from rotator cuff tears can lead to secondary
osteoarthritis [8].
Patients with rotator cuff disease may have tendinopa-
thy (whereby the tendon is structurally intact) or a ten-
don tear. Tendon tears are sub-classified according to
tear sizes ranging from small (<1 cm) to massive (>5 cm
in length) [9]. Tendons heal by fibrosis and the scar repair
is frequently structurally and functionally inferior to nor-
mal tendon, increasing the risk of re-injury [10–13].
Treatment for shoulder tendinopathy includes physiother-
apy, non-steroidal anti-inflammatory drugs (NSAIDs), and
interventional treatments including local infiltration with
glucocorticoids, platelet-rich plasma (PRP) and arthro-
scopic acromioplasty or rotator cuff repair. Non-operative
strategies are associated with mixed patient outcomes
[14]. Furthermore, surgical repairs of torn rotator cuff
tendons are associated with high failure rates of up to
94 % [15].
Inflammation is known to drive fibrotic repair in skin,
liver, renal and pulmonary diseases. Signal transducer
and activator of transcription (STAT)-6 pathways
encompassing interleukin (IL)-13/IL-4 are thought to be
the dominant pro-fibrotic axis for increasing collagen
synthesis from fibroblasts and regulating alternatively ac-
tivated macrophages [16–19]. Upregulation of IL-13 has
been shown to mediate tissue fibrosis via transforming
growth factor (TGF)β [20]. TGFβ is the most frequently
investigated effector of fibrosis and regulator of extracel-
lular matrix (ECM) turnover. The TGFβ superfamily
modulates a number of vital cellular processes in tissue
development, differentiation and homeostasis. TGFβ-1 is
pivotal to wound healing processes and implicated in
multiple fibrotic disease states including connective tis-
sue fibrosis [21]. TGFβ is synthesised as a pro-peptide,
and is abundant within the ECM, platelets and macro-
phages. Signalling is mediated through binding of active
TGFβ to a heteromeric complex of TGFβ receptor (R)1
and 2, resulting in SMAD3 phosphorylation and activa-
tion of target genes. Macrophages, lymphocytes and resi-
dent stromal cells are key cell populations implicated in
the propagation of fibrotic disease. Whilst inflammation
has been identified in diseased tendons [22, 23], little is
known about the inflammatory mechanisms driving ten-
don fibrosis.
Animal models have been used to identify potential
treatment strategies for fibrotic diseases. These include
manipulation of pro-fibrotic pathways through exogen-
ous anti-TGFβ, antisense-TGFβ gene, SMAD3 knockout,
and macrophage depletion models [24–29]. Reducing
TGFβ signalling diminishes the fibrotic phenotype of
tendon but also reduces tissue tensile strength [30]. As
part of the TGFβ superfamily, bone morphogenic pro-
teins (BMPs) have previously been investigated for their
role in tendon-to-bone healing [27, 31, 32] and in the
stimulation of rotator cuff tendon-derived cells in tissue
culture models [33]. These studies show BMP-2 and -7
induce collagen production in rotator cuff tendon-
derived cells, suggesting these BMPs could play a role in
the development of tendon fibrosis.
Little is known of the mechanisms underpinning fibro-
sis in diseased human tendons. To our knowledge, no
study to date has investigated TGFβ superfamily expres-
sion in diseased human tendons from living patients.
The aim of this study was to investigate mRNA and pro-
tein expression of key TGFβ superfamily members in tis-
sue samples from patients with established tendon disease
compared to healthy control tendons. We hypothesised
that expression of TGFβ superfamily genes and proteins
would be dysregulated in diseased compared to healthy
tendons.
Methods
Diagnosis of rotator cuff tendon disease in patient
cohorts
Patients presenting to a referral shoulder clinic had
failed non-operative treatment, including a course of
physical therapy, and glucocorticoid injections into the
sub-acromial space, and had experienced pain for a
minimum of 6 months. Patients had not received gluco-
corticoid or PRP for 12 weeks before surgery. A shoulder
specialist diagnosed sub-acromial impingement syn-
drome in all patients. Impingement tests were positive
in all patients. High-definition ultrasound examination
was performed in all patients to determine if there was
evidence of a rotator cuff tear and also to identify abnor-
mal echogenic changes at the supraspinatus footprint.
Exclusion criteria for all patients in this study included
previous shoulder surgery, dual shoulder pathological
lesions, significant problems in the other shoulder,
rheumatoid arthritis or systemic inflammatory disease,
osteoarthritis or significant neck problems.
Patient cohort for gene expression analysis
Torn rotator cuff (supraspinatus, n = 7) and healthy
hamstring (n = 7) tendon tissue samples were collected
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to investigate mRNA expression of TGFβ superfamily
members in these samples. Healthy hamstring tendons
were collected from patients undergoing anterior cruciate
ligament (ACL) reconstruction surgery from male and fe-
male patients aged between 22 and 49 (mean 31 ± 9.5)
years. Torn supraspinatus tendon tissues were col-
lected from male and female patients aged 40 to 67
(mean 52.5 ± 9) years (Table 1). Fresh tissue samples
were immediately snap frozen in liquid nitrogen and
stored at –80 °C prior to RNA extraction.
RNA extraction and cDNA synthesis
Frozen tissue samples stored at –80 °C were homoge-
nised in 1 mL RNABee (AMS Biotechnology, UK) using
an IKA Ultra Turrax T8 Homogeniser (Fischer Scientific,
UK). RNA extraction was carried out as per the manu-
facturer’s protocol using an RNeasy mini kit (Qiagen,
Limburg, Netherlands) with an on-column DNA treat-
ment using DNase 1 (Thermo Scientific, UK). RNA con-
centration and quality were determined by measuring
the ratio of absorbance at 260:280 nm using a NanoDrop
100 spectrophotometer (Thermo Scientific, MA, USA),
with all samples achieving a minimum ratio of 1.80.
RNA (250 ng) was reverse transcribed using a High
Capacity Reverse Transcription Kit (4368813, Applied
Biosystems, UK).
Gene expression by quantitative real-time polymerase
chain reaction
cDNA was diluted to 2.5 ng/μL with RNase free water
and 5 μL was used in a 20 μL quantitative polymerase
chain reaction (qPCR) with Fast SYBR Green Master Mix
(4385612, Applied Biosystems). Validated human primers
included TGFB1 (QT00000728), TGFBR1 (QT00083412),
TGFBR2 (QT00014350), BMP2 (QT00012544), BMP7
(QT00068936), and CTGF (QT00052899) (Qiagen).
Duplicate reactions for each gene were run on a ViiA7
qPCR machine (Applied Biosystems, CA, USA) and the
mean value for these duplicates calculated and used for
analysis. Results were calculated using the ΔΔCt method
and normalized against β-actin and GAPDH reference
genes. Results were consistent with both reference genes
and data shown are normalized to β-actin.
Patient cohort for immunohistochemistry
For this controlled laboratory study, torn supraspinatus
tendons were collected at the time of surgery from the
edges of torn tendons from symptomatic male and fe-
male patients with full thickness tears aged between 50
and 78 years (Table 1). Samples of intact tendinopathic
supraspinatus were collected from male and female pa-
tients at the time of arthroscopic acromioplasty. All pa-
tients had loss of shoulder function and/or shoulder pain
as reflected in a median Oxford shoulder score (OSS) of
29 [34]. Healthy supraspinatus tendon samples were col-
lected from patients who underwent surgery for shoulder
instability and who had an intact non-degenerative supras-
pinatus tendon on ultrasound confirmed at surgery.
Healthy patients were aged between 18 and 29 years
(Table 1). For patients undergoing general anaesthesia for
shoulder stabilization or arthroscopic acromioplasty, a
biopsy was taken using ultrasound guidance whilst the pa-
tient was anaesthetized and prior to the surgical proced-
ure. A percutaneous ultrasound-guided biopsy technique
was performed as previously described [35] to acquire
healthy tissue 5–10 mm posterior to the anterior edge of
the tendon.
Tissue processing
Samples were immersed in 10 % buffered formalin for
1 week. After fixation, tendons were processed using a
Leica ASP300S tissue processor and embedded in paraf-
fin wax. Tissues were sectioned at 4 μm using a rotary
microtome (Leica Microsystems Ltd, UK) and collected
Table 1 Patient demographics for the study group
Cohort n Median age (years) Sex (M:F) History Treatment Median OSS
Healthy supraspinatus 10 24 (18–29) 9:1 Shoulder instability Shoulder stabilisation N/A
Healthy hamstring (mRNA) 7 31 (22–49) 3:4 ACL rupture ACL repair N/A









Torn supraspinatus (mRNA) 7 52.5 (40–67) 5:2 3 medium Rotator cuff repair 26 (9–31)
2 large
2 massive
ACL anterior cruciate ligament, F female, M male, N/A not available, OSS Oxford shoulder score, PRP platelet-rich plasma, SAD sub-acromial decompression surgery
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onto adhesive glass slides and baked at 60 °C for 30 minutes
and 37 °C for 60 minutes.
For antigen retrieval, slides were baked at 60 °C for
60 minutes and combined deparaffinization and antigen
retrieval was performed by submerging slides in FLEX
TRS antigen retrieval fluid using a PT Link machine
(Dako, Glostrup, Denmark). Immunostaining was per-
formed using an Autostainer Link 48 machine using the
EnVision FLEX visualisation system (Dako). Primary
antibodies against TGFβ family mediators included
TGFβ-1 (ab64715), TGFβ R1 (ab31013) and TGFβ R2
(ab78419) (Abcam Cambridge, UK). Antibody binding
was visualized using FLEX 3,3′-diaminobenzidine (DAB)
substrate working solution and haematoxylin counter-
stain (Dako) as per protocols provided by the manufac-
turer. Isotype control antibodies included mouse IgG1,
IgG2a, IgG2b, IgG3 and IgM, (Dako). All antibodies were
validated in-house to ensure the recommended concen-
tration produced positive staining with minimal artifact
on supraspinatus tendon tissue. After staining, slides
were rehydrated in alcohols and xylene and mounted
using Pertex mounting medium (Histolab, Gothenburg,
Sweden).
Immunofluorescence for co-localization of TGFβ with
macrophage markers
Immunofluorescence staining of sections of massive
supraspinatus tendon tears is described in detail else-
where [22]. Briefly, after antigen retrieval, tissues were
blocked in 5 % goat serum (Sigma) at room temperature.
Sections were incubated with the primary antibody cock-
tail (macrophage markers CD206 ab117644, CD163
LS_C174770 and pan TGFβ ab66043) diluted in 5 %
normal goat serum in phosphate-buffered saline (PBS)
for 2 hours. Slides were washed in PBS with Tween and
incubated in the secondary antibody cocktail (goat anti-
mouse FITC IgG1 (Southern Biotech), goat anti-mouse
IgG2a Alexa Fluor 568, and goat anti-rabbit IgG Alexa
Fluor 633 (Life Technologies)) diluted in 5 % normal
equine serum (Sigma) for 2 hours. After washing, sec-
tions were incubated in 2 μM POPO-1 nuclear counter-
stain (Life Technologies) diluted in PBS containing
0.05 % Saponin (Sigma). Tissue autofluorescence was
quenched with a solution of 0.1 % Sudan Black B (Appli-
chem). Slides were mounted using fluorescent mounting
medium (VectaShield), sealed and stored at 4 °C until
image acquisition. For negative controls the primary
antibody was substituted for universal isotype control
antibodies: cocktail of mouse IgG1, IgG2a, IgG2b, IgG3
and IgM (Dako) and rabbit immunoglobulin fraction of
serum from non-immunised rabbits, solid phase
absorbed (Dako). Stained slides were visualised on a
Zeiss LSM 710 confocal microscope as previously de-
scribed [22].
Image analysis for quantitative immunohistochemistry
Twenty images of immunostained sections (or until
exhausted) were taken on a Zeiss inverted microscope
(Zeiss, Cambridge, UK) using Axiovision software (Zeiss)
at ×100 magnification with oil immersion. Images were
collected systematically to ensure no overlap and to avoid
areas of artefact or fold in the tissue sample. ImageJ
(National Institutes of Health, Bethesda, Maryland,
USA) was used to analyse the images, employing a pre-
viously validated algorithm that quantifies DAB staining
by a colour deconvolution method [36, 37]. The quanti-
fication system used compared the number of nuclei to
the amount of immunopositive staining to account for
tissue cellularity.
Statistical analysis
Statistical analysis was performed using GraphPad Prism
6 (GraphPad, CA, USA). Normality was tested using a
Shapiro-Wilk test. Kruskal-Wallis tests were used to
compare expression of TGFβ superfamily at mRNA
and protein levels in samples of healthy, tendinopathic
and torn tendons. p < 0.05 was considered statistically
significant.
Study approval
Ethical approval for this study was granted by the local
research ethics committee: Oxfordshire REC B refs: 10/
H0402/24, 10/H0605/35, 09/H0605/111, 09/H0606/11.
Full informed consent according to the Declaration of
Helsinki was obtained from all patients.
Results
Diseased tendons show dysregulation of TGFβ family
mediators at the mRNA level
Expression of TGFB1, TGFBR1, and TGFBR2 genes were
investigated in torn rotator cuff and healthy hamstring
tendons. TGFBR1 mRNA was decreased in diseased ro-
tator cuff compared to healthy tendons (p = 0.048, two-
fold); in contrast, TGFBR2 was increased (p = 0.048,
threefold) (Fig. 1). There was a trend for reduced TGFB1
in diseased compared to healthy hamstring tendons.
BMPs have been shown to signal via homodimeric re-
ceptors from the TGFβ superfamily, and are also impli-
cated in fibrotic pathways. There was no significant
difference in BMP2 mRNA between healthy hamstring
and torn rotator cuff tendons (Fig. 1). BMP7 was not de-
tected in torn rotator cuff tendons; however, this was
not significantly different compared with healthy ham-
string. Connective tissue growth factor (CTGF) was also
investigated as a pro-fibrotic cytokine and downstream
effector of TGFβ. There was a trend for reduced CTGF
in torn rotator cuff compared to healthy hamstring
tendons.
Goodier et al. Arthritis Research & Therapy  (2016) 18:48 Page 4 of 10
Histological assessment of diseased rotator cuff tendons
Tendon tissues from patients with supraspinatus tendi-
nopathy or tears showed marked disorganization of the
tendon ECM and collagen fibrils and increased vascular-
ity. Histological assessment of tendons collected from
this cohort was performed on haematoxylin and eosin
stained sections using the Bonar scoring system (0–12)
evaluating tissue structure, and is reported in a previous
published study [22]. Median and interquartile ranges of
healthy supraspinatus tendons exhibited more normal
tissue architecture (Bonar score of 2, range 1–2) com-
pared to tendinopathic (7, range 6–8) and torn supras-
pinatus tendons (10, range 8.25–10).
Diseased tendons show downregulation of TGFβ
superfamily proteins
Expression of TGFβ-1, TGFβ R1, and TGFβ R2 proteins
was investigated in healthy, tendinopathic and torn rotator
cuff tendons (Fig. 2). Immunopositive staining for TGFβ
superfamily proteins was identified in angiofibroblastic
and ECM regions of tendons. Quantitative analyses of
immunopositive staining showed expression of TGFβ-1,
TGFβ R1, and TGFβ R2 proteins were significantly re-
duced in diseased tendons compared to healthy samples
(Fig. 3). Specifically, TGFβ-1 protein was reduced in torn
(p = 0.0123, 2.6-fold) and tendinopathic (p = 0.0064, three-
fold) compared to healthy tendons. TGFβ R1 protein was
reduced in torn compared to healthy and tendinopathic
tendons (p = 0.0002, 30-fold and p = 0.0018, 21-fold, re-
spectively). TGFβ R2 was reduced in torn compared to
healthy tendons (p = 0.0087, sevenfold reduction); tendi-
nopathic tissues showed almost no expression of TGFβ
R2 compared to healthy tendons (p < 0.00001, 183-fold re-
duction). Isotype control staining of diseased rotator cuff
tendons is shown in Fig. 4.
Macrophages in diseased tendons express TGFβ
Macrophages are known to be important immune cell
populations in diseased rotator cuff tendons and their
activation status has been shown to change with disease
stage [22]. We investigated if myeloid cells in samples of
chronic fibrosed tendon tears expressed pan-TGFβ.
Antibody labelling with macrophage markers CD206
and CD163 (representing STAT-6 and glucocorticoid re-
ceptor macrophage activation pathways, respectively)
and pan-TGFβ showed co-localization of these three
markers in sections of a massive supraspinatus tendon
tear (Fig. 5).
Discussion
This study of diseased tendons from well-phenotyped
patient cohorts investigates expression of the TGFβ
superfamily members in healthy, tendinopathic, and torn
tendons. Compared to healthy tendons, diseased tendons
showed dysregulation of TGFβ superfamily members.
We identify suppression of TGF-β1 and TGFβ R1
Fig. 1 Expression of pro-fibrotic genes in healthy and diseased tendons. a–c TGFβ family mediators, d BMP-2 and e BMP-7, and f CTGF mRNA
expression are shown in healthy hamstring (n = 7) compared to diseased rotator cuff tendons (n = 7). Gene expression is normalized to β-actin;
bar shows median value. Data were analysed using the Kruskal-Wallis test; *p < 0.05. BMP bone morphogenic protein, CTGF connective tissue
growth factor, TGF transforming growth factor, TGF R transforming growth factor receptor
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mRNA and proteins in diseased compared to healthy
tendons. Conversely TGFBR2 mRNA was increased in
diseased tendons. This disruption of the TGFβ axis with
tendon disease suggests these pathways may have im-
portant roles in tendon homeostasis.
The progression from rotator cuff tendinopathy to tear
represents a continuum. Patients with tendon tears have
reduced likelihood of repair [13]. We found no differ-
ence in symptom duration between patients with intact
and torn tendinopathic tendons suggesting that pain is
not always associated with tendon disease. Throughout
the disease spectrum, the role of TGFβ superfamily me-
diators and the mechanisms underpinning tendon fibro-
sis remain understudied. Knowledge of these pathways is
better described in fibrotic diseases of other connective
tissues including pulmonary and renal tissues where in-
creased levels of TGFβ and subsequent collagen produc-
tion are reported in animal and human tissues [38–40].
In these tissues TGFβ-1 is known to modulate the inflam-
matory response by influencing fibroblast and macrophage
Fig. 3 Quantitative analysis of immunopositive staining showing dysregulation of TGFβ family proteins in diseased compared to healthy rotator
cuff tendons. a TGFβ-1: healthy (n = 11), tendinopathic (n = 10), torn (n = 10); b TGFβ R1: healthy (n = 10), tendinopathic (n = 10), torn (n = 9);
and c TGFβ R2: healthy (n = 10), tendinopathic (n = 10), torn (n = 9). Bar represents the median value. Data were analysed using the Kruskal-Wallis test;
*p < 0.05 **p < 0.01 ***p < 0.001 ****p < 0.0001. TGF transforming growth factor, TGF R transforming growth factor receptor
Fig. 2 Photomicrographs showing immunostaining for TGFβ1, TGFβ R1 and TGFβ R2 in healthy, tendinopathic and torn rotator cuff tendons.
Representative images of DAB immunostaining (brown) are shown. Nuclear counterstain (blue) is haematoxylin. Scale bar = 20 μm. TGF
transforming growth factor, TGF R transforming growth factor receptor
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recruitment, stimulating collagen production and
downregulating proteinase activity [18, 41]. TGFβ has
been shown to regulate epithelial–mesenchymal transi-
tion (EMT), potentially generating another source of
collagen-producing cells [42]. In tendon, TGFβ is
stored in the ECM and released in response to exercise
and strain, regulating collagen synthesis and acting as
a mechanical transducer [43, 44]. Sakai et al. showed
an increase in total TGFβ protein when comparing tissue
from patients with rotator cuff tendon tears and anterior
shoulder instability [45]. In contrast, Fenwick et al. found
no evidence of TGFβ-1 protein in chronic tendinopathy
or normal cadaveric human tendon tissues [46]. Chang et
al stimulated and inhibited TGFβ-induced collagen pro-
duction in a surgical animal model to investigate flexor
tendon adhesions demonstrating the importance of TGFβ
in fibrotic healing [24].
In this study, we show that TGFβ-1, TGFβ R1 and
TGFβ R2 protein levels are reduced in diseased com-
pared to healthy rotator cuff tendons. We propose this
could be a protective response to limit the hypertrophic
fibrosis characteristic of tendon disease. Healthy rotator
cuff tendons showed a variable range of expression of
TGFβ receptors and ligands, perhaps demonstrating
more active regulation of tissue homeostasis by TGFβ in
healthy compared to diseased tendons. This suggests an
important homeostatic function similar to those pro-
posed in skin, cartilage and vascular tissue where dysreg-
ulation can result in disease [47–51]. It is conceivable
that the downregulation of TGFβ superfamily proteins
in established disease could further reduce the ability of
the tendon to heal. This may be exacerbated in torn ten-
dons by their reduced ability to transmit strain, which
would then suppress the mechanical stimulus to regulate
TGFβ signalling [43]. Fibrotic pathways independent of
TGFβ, such as tumour necrosis factor alpha, may be ac-
tivated resulting in them becoming a more dominant
driving force in chronic tendon disease [52].
TGFβ mRNA and protein have been shown to increase
in animal models of acute-stage tendon healing. How-
ever, these models of surgical tendon transection may
not accurately recapitulate chronic human tendon path-
ology [53, 54]. The tendon samples used in the current
study represent chronic-stage tendon disease. We specu-
late that expression of TGFβ family mediators in human
rotator cuff tendons would be increased during acute-
stage pathology, and then decline in chronic disease as
reported in the current study. Future work should investi-
gate the temporal regulation of members of the TGFβ
superfamily and of alternative fibrotic pathways including
Fig. 4 Isotype control staining of diseased human rotator cuff tendons. Panel shows representative images of diseased tendon sections stained
with isotype control antibodies for mouse IgG1, IgG2a, IgG2b and rabbit IgG fractions. Nuclear counterstain is haematoxylin. Scale bar = 50 μm.
Ig immunoglobulin
Fig. 5 Representative immunofluorescence images of a massive supraspinatus tendon tear stained for macrophage activation markers including
those in the STAT-6 pathway (CD206, green), the glucocorticoid receptor pathway (CD163, red) with pan-TGFβ (purple). Cyan represents POPO-1
nuclear counterstain. Scale bar = 20 μm. CD cluster of differentiation, TGF transforming growth factor
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Wnt, PI3K and vascular endothelial growth factor in pa-
tients with early through to established tendon disease.
Although we demonstrate downregulation of TGFβ
signalling mediators with established tendon disease,
TGFBR2 mRNA was upregulated in tendon tears. This
observation may represent a potential aberration in the
translation of TGFBR2 mRNA into protein. Alterna-
tively, upregulation of TGFBR2 could be an attempt to
support higher levels of alternatively activated macro-
phages [55]. We identified CD206high and CD163high
macrophages that co-expressed pan-TGFβ in a massive
tendon tear, suggesting M2 macrophages may be a source
of TGFβ in advanced stage tendon disease.
TGFβ pathways have been investigated as potential
therapeutic targets to modulate fibrosis, adhesions, and
hypertrophic scarring [24, 26, 28, 30]. However, anti-
TGFβ models also resulted in reduced tissue tensile
strength [30, 56]. In a model of stress-shielding, exogen-
ous TGFβ helped maintain tendon strength, whereas
anti-TGFβ accelerated the loss of strength [56]. These
studies and our results support the concept that TGFβ
has a fundamental role in tendon homeostasis as well as
playing a role in fibrosis.
CTGF is an effector cytokine of TGFβ that increases
deposition of ECM and promotes myofibroblast differen-
tiation. With significantly reduced TGFβ in tendon dis-
ease, it might be expected that CTGF would also be
decreased. However, in the current study no significant
difference was seen in CTGF mRNA expression between
healthy and diseased tendons. It is possible that other
signalling pathways could influence CTGF mRNA ex-
pression. It has been suggested that CTGF can be inde-
pendently expressed via the IL-13 pathway [57] which is
implicated in alternative activation of macrophages. This
is an interesting observation in light of the high levels of
monocytes and macrophages observed in chronic rotator
cuff tendinopathy [22].
BMPs are a sub-group of the TGFβ superfamily and
are known to play developmental and homeostatic func-
tions in most tissues [58]. BMP-2 and -7 have been
shown to increase collagen production in rotator cuff
cells, and could both be implicated in a fibrotic pheno-
type [33]. Furthermore BMP-2 may, like TGFβ, be in-
creased in response to strain [59]. However, we found
no significant difference in mRNA expression of BMP2
or BMP7 in healthy and diseased tendons.
There are several limitations to this study. We did not
investigate expression of other isoforms of TGFβ includ-
ing TGFβ-2 and TGFβ-3 or expression of phospho-
SMAD signalling. The samples from the current study
were obtained from patients with established tendon dis-
ease. It is necessary to ascertain the temporal nature of
TGFβ signalling in the more acute stage of tendinopathy
and early stages of fibrosis. However, acquiring these
samples of early-stage human tendon disease presents a
number of challenges. We acknowledge there are limita-
tions with the use of the hamstring tendon as a com-
parator to diseased tendons including tendon type and
age differences. However, hamstring tendon was taken
from live healthy donors with no history of tendon
disease. We believe this is a more suitable compara-
tor than cadaveric rotator cuff tendon tissues where
little is known about whether the tendons were
healthy or diseased and the influence of postmortem
change.
The findings from our study showing downregulation
of TGFβ superfamily members in established disease
suggest that these patients are unlikely to benefit from
therapeutic TGFβ blockade, which has been investigated
as a treatment strategy in several animal models. Im-
proved understanding of fibrotic processes in diseased
human tendons is essential to inform therapeutic target
discovery. Future studies should focus on investigating
the expression profiles and mechanisms of fibrosis in
tendon tissues obtained from longitudinal patient co-
horts, from early to advanced disease and both before
and after treatment.
Conclusions
We demonstrate dysregulation of the TGFβ axis in
chronic human rotator cuff tendon disease and propose
this may be a protective mechanism to further limit fi-
brosis. Our findings also suggest TGFβ pathways may
have an important role in tendon homeostasis. Further
work is needed to investigate TGFβ-related pathways in
healthy and diseased tendons, their roles in early-stage
tendon pathology and the contribution of alternative
pathways in the development of tendon fibrosis.
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